score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical	Clinical evidence		Copy Number	PTEN	Deletion				0.0	0.0		Putatively Actionable	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Putatively Actionable	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001						0				PTEN Deletion	1.0	MEL-IPI_Pat45	MEL-IPI_Pat45-Tumor-SM-4DK26	
Putatively Actionable			Guideline	Copy Number	TP53	Deletion				0.0	0.0																Putatively Actionable	0.0	Deletion of 17p13 leads to LoH of TP53 and is considered a high-risk feature of multiple myeloma.	National Comprehensive Cancer Network. Multiple Myeloma NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf	0				TP53 Deletion		MEL-IPI_Pat45	MEL-IPI_Pat45-Tumor-SM-4DK26	
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat45		
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R805Q	0.2153	144.0	3.3e-05	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007													0	203.0	0.2414	1.0	ATM p.R805Q (Missense)	1.0	MEL-IPI_Pat45	MEL-IPI_Pat45-Tumor-SM-4DK26	MEL-IPI_Pat45-Normal-SM-53U5R
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S241F	0.9327	104.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0.0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	243.0	0.963	1.0	TP53 p.S241F (Missense)		MEL-IPI_Pat45	MEL-IPI_Pat45-Tumor-SM-4DK26	MEL-IPI_Pat45-Normal-SM-53U5R
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Frameshift	p.L1170fs	0.4459	222.0	0.0	0.0																Investigate Actionability	0.0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	0.0	0.0	0.0	ASXL1 p.L1170fs (Frameshift)		MEL-IPI_Pat45	MEL-IPI_Pat45-Tumor-SM-4DK26	MEL-IPI_Pat45-Normal-SM-53U5R
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Frameshift	p.L1170fs	0.3837	258.0	0.0	0.0																Investigate Actionability	0.0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	0.0	0.0	0.0	ASXL1 p.L1170fs (Frameshift)		MEL-IPI_Pat45	MEL-IPI_Pat45-Tumor-SM-4DK26	MEL-IPI_Pat45-Normal-SM-53U5R
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat45		
Investigate Actionability	Guideline			Somatic Variant	ERBB2	Splice Site	p.G408D	0.4146	164.0	0.0	0.0		Investigate Actionability	Ado-Trastuzumab Emtansine	ER signaling inhibition	Hormone therapy	Ado-trasuzumab emtansine is an available targeted agent with activity against ERBB2 variants in metastatic, NSCLC.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf													0	81.0	0.3457	1.0	ERBB2 p.G408D (Splice Site)		MEL-IPI_Pat45	MEL-IPI_Pat45-Tumor-SM-4DK26	MEL-IPI_Pat45-Normal-SM-53U5R
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Missense	p.L1103S	0.5135	259.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0	5.0	0.4	0.2071	BRCA2 p.L1103S (Missense)		MEL-IPI_Pat45	MEL-IPI_Pat45-Tumor-SM-4DK26	MEL-IPI_Pat45-Normal-SM-53U5R
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.R222*	0.013999999999999999	500.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981													0	81.0	0.0	0.0532	FBXW7 p.R222* (Nonsense)		MEL-IPI_Pat45	MEL-IPI_Pat45-Tumor-SM-4DK26	MEL-IPI_Pat45-Normal-SM-53U5R
Investigate Actionability	Preclinical			Copy Number	AURKB	Deletion				0.0	0.0		Investigate Actionability	Barasertib	Aurora-B kinase inhibition	Targeted therapy	MYC amplified small cell lung cancer	Helfrich BA, Kim J, Gao D, et al. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Mol Cancer Ther. 2016;15(10):2314-2322.	https://doi.org/10.1158/1535-7163.MCT-16-0298													0				AURKB Deletion		MEL-IPI_Pat45	MEL-IPI_Pat45-Tumor-SM-4DK26	
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Splice Site	p.P523L	0.4191	272.0	8e-06	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405						0	82.0	0.4512	1.0	BCR p.P523L (Splice Site)		MEL-IPI_Pat45	MEL-IPI_Pat45-Tumor-SM-4DK26	MEL-IPI_Pat45-Normal-SM-53U5R
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.R146L	0.0268	149.0	0.0	0.0																Investigate Actionability	0.0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	205.0	0.039	0.7914	STAG2 p.R146L (Missense)		MEL-IPI_Pat45	MEL-IPI_Pat45-Tumor-SM-4DK26	MEL-IPI_Pat45-Normal-SM-53U5R
Biologically Relevant				Somatic Variant	ROS1	Nonsense	p.Q2212*	0.439	410.0	0.0	0.0																					0	0.0	0.0	0.0	ROS1 p.Q2212* (Nonsense)		MEL-IPI_Pat45	MEL-IPI_Pat45-Tumor-SM-4DK26	MEL-IPI_Pat45-Normal-SM-53U5R
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.A67V	0.8902	82.0	0.0	0.0																					0	0.0	0.0	0.0	CDKN2A p.A67V (Missense)		MEL-IPI_Pat45	MEL-IPI_Pat45-Tumor-SM-4DK26	MEL-IPI_Pat45-Normal-SM-53U5R
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.R802C	0.5489	184.0	0.0	0.0																					0	265.0	0.0189	1.0	COL1A1 p.R802C (Missense)		MEL-IPI_Pat45	MEL-IPI_Pat45-Tumor-SM-4DK26	MEL-IPI_Pat45-Normal-SM-53U5R
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.PPA66del (Deletion)		MEL-IPI_Pat45		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.911																									0				COSMIC Signature (version 2) 7 (91%)		MEL-IPI_Pat45		
